Status:
COMPLETED
Early Interventional Treatment for Cancer Pain
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Medtronic
Conditions:
Cancer Pain
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
The purpose of the study is to evaluate how feasible and beneficial it is to refer patients with cancer pain to a doctor who specializes in pain management, including procedures to relieve pain, and w...
Detailed Description
This is a single arm pilot study evaluating a new system of referral and pain evaluation for patients with advanced solid tumors and moderate-to-severe pain who are not already on high-dose opioids to...
Eligibility Criteria
Inclusion
- Diagnosis of a metastatic, or locally advanced unresectable malignancy
- Anticipated prognosis of more than 6 months according to the primary oncologist
- Age greater than 21 years
- Persistent pain with an average pain rating of 4 or greater on an 11-point numeric rating scale (NRS) from 0-10 where 10 is considered the most severe.
- Pain has persisted for at least 2 weeks
- Pain is due to cancer or sequelae of cancer treatment
Exclusion
- Primary pain syndrome is sensory peripheral neuropathy
- Patient is taking more than 200 morphine milligram equivalents (MMEs) per day on average, at the time of recruitment.
- Currently cared for by interventional pain management specialist
- Receipt of prior pain intervention (e.g. celiac neurolysis)
- Bleeding diathesis, uncontrollable infection, or other contra-indications to pain interventions
- History of opioid misuse disorder
- Inability to speak English
- Cognitive impairment or any other disorder that would impede study participation and survey completion
- If patients are unable to complete the baseline survey, they will no longer be considered eligible for the study; this will serve as an indication of barriers to participation that would make them unable to comply with study procedures.
Key Trial Info
Start Date :
June 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05366413
Start Date
June 2 2022
End Date
October 26 2024
Last Update
April 16 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215